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Summary
Background: Infection by Helicobacter pylori (Hp) has been linked to extradigestive pathologies including
ischemic cerebral disease. The aim of our study was to assess the relationship between chronic
Hp infection and ischemic stroke risk factors.
Material/Methods: 80 patients (pts) aged 60–75 years with ischemic stroke confirmed by CT scans (group I) and
80 age- and gender-matched healthy controls (group II) were included into trial. Atheroscle-
rotic plaques from 20 Hp positive pts were obtained at carotid endarterectomy for Hp DNA
assessment by PCR. In all groups following parameters were determined; 1) the prevalence of
Hp infection using 13C-Urea Breath Test (UBT), 2) plasma anti-Hp and anti-CagA IgG and
interleukin-8 (IL-8), and 3) plasma lipids and fibrinogen. Hp positive pts and controls
received one-week anti-Hp therapy and after six months total cholesterol, low-density
lipoprotein (LDL)-cholesterol, fibrinogen and IL-8 levels were re-examined.
Results: Hp infection was detected by UBT in 83.75% of stroke pts but only in 65% of controls. CagA
seropositivity was also significantly higher in stroke pts (57.5%) than in controls (33.75%).
Plasma levels of cholesterol, LDL-cholesterol and fibrinogen as well as IL-8 were significantly
higher in Hp positive subjects, especially in pts with ischemic stroke. Six months following suc-
cessful anti-Hp therapy, the plasma levels of total cholesterol, LDL-cholesterol, fibrinogen and
IL-8 were significantly lower than those in Hp positive stroke pts and controls.
Conclusions: Hp infection represents risk factor of ischemic stoke via an interaction of Hp cytotoxins or
cytokines with atherosclerotic plaques in carotic arteries.
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BACKGROUND
Helicobacter pylori (Hp) is a Gram-negative microaerophi-
lic bacterium that colonizes gastric mucosa and that is
considered as the main etiological factor in chronic acti-
ve gastritis and a risk factor for peptic ulcers and gastric
cancer [1,2]. Seroprevalence of Hp infection was found
positive in about 50% of the world population and the
results showed higher Hp infection in developing than
in developed countries. Hp infection was also increased
with the age of population [3].
Recent evidence indicates that local and systemic immu-
nological response elicited by Hp infection is an impor-
tant factor not only for the gastric mucosal damage but
also for the extradigestive pathologies [4–6]. Clinical pa-
thology of Hp-infected gastric mucosa depends upon
the expression of bacterial CagA and VacA cytotoxins
and immunological responses, particularly the release of
proinflammatory cytokines in infected subjects [7–9].
Production of excessive amounts of proinflammatory
factors and cross mimicry between bacterial and host
antigens may contribute to the development of gastric
mucosal damage and extradigestive manifestations asso-
ciated with this infection [10–13]. Hp infection has been
epidemiologically linked to some extradigestive condi-
tions such as idiopathic thyreoiditis and some skin dise-
ases [4,6,14,15]. It has been also associated with ische-
mic coronary heart and cerebral vascular diseases, but
the number of supporting publications is relatively small
and the results obtained are often contradictory and po-
orly controlled [16–21].
Diabetes, hyperlipemia, alternations in clotting factors,
hypertention, smoking, obesity and life style are well re-
cognized modifying factors and age is the major unmo-
difying factor for the development of atherosclerosis
and ischemic cerebral disease [22]. Recently, several stu-
dies performed in vitro on serum and vascular tissue
specimens provided evidences for participation of infec-
tious, bacterial and viral, factors in the pathogenesis of
atherosclerosis [23–27]. Studies in humans and animals
also emphasized the importance of infectious factors in
atherogenesis [10,11,28,29].
Hp infection is one of the most widely spread infections
in humans and its prevalence is positively correlated
with age of population [3]. Acute ischemic stroke in Po-
land remains the fourth major cause of mortality and its
prevalence also increases with the age of population
[30]. Higher levels of proinflammatory and procoagu-
lant factors such as: C-reactive protein (CRP), increased
leukocyte blood count, enhanced fibrinogen concentra-
tion and altered plasma lipid profile were observed in
subjects infected with Hp [31-34]. There are discrepan-
cies regarding the influence of Hp infection on major
plasma biochemical risk factors of atherogenesis. Accor-
ding to some authors the Hp infection enhances athero-
sclerosis by altering the plasma concentrations of bio-
chemical indices of atherogenesis [35-38], but others be-
lieve that bacterium directly contributes to the atheroge-
nesis by induction of chronic inflammatory response in
vascular wall without major alterations in biochemical
atherosclerotic risk factors [39–42]. It is well-known that
chronic Hp infection enhances plasma levels of proin-
flammatory interleukins (IL), including IL-1, IL-6, IL-8
and tumor necrosis factor α (TNF α) [10]. IL-8 may
play an important role in recruitment and activation of
inflammatory cells, which are the key factors in initia-
tion and progression of atheromathic processes [43-45].
Increased concentrations of IL-8 were detected mainly
in cerebrospinal fluid (CSF) and also in serum of pa-
tients with ischemic stroke during the first month after
ischemic brain injury [46].
Earlier studies have reported an association between
chronic gastric mucosa Hp infection and ischemic heart
or cerebral diseases [16-18,34], however, the possible
mechanisms by which Hp-induced gastric inflammation
could cause atherogenesis remains unknown.
The main purpose of this study was to assess the rela-
tionship between chronic Hp infection and acute ische-
mic stroke in elderly persons with special reference to
the influence of Hp strain cytotoxicity on some blood
chemicals implicated in atherogenesis.
MATERIAL AND METHODS
Eighty non-diabetic, non-smokers of similar social class
patients (pts), 60–75 years old, with first-ever signs of
acute ischemic cerebral stroke due to large vessel dise-
ase admitted consecutively to a Neurological Cerebrova-
scular Department of Neurological Clinic in 1999 and
2000 year were enrolled into the study (group I). Stroke
pts due to cardioembolism or of unknown etiology were
not included to the study. Ischemic cerebral stroke in
supratentorial area in our pts were confirmed by com-
puted tomography (CT). CT scans were performed at
first and fourth days of clinical manifestation of the dise-
ase.
Control group was recruited from 80 age-, gender- and
socioeconomic status-matched persons without any neu-
rological symptoms (group II). In addition, twenty Hp
positive pts with critical stenosis of common carotid ar-
tery, confirmed ultrasonographically by duplex ultraso-
und and angiographically, were included into the study
(group III). Each patient from each study group was
examined using CT, carotid duplex ultrasound and
electrocardiography (ECG).
Determination of Hp infection status in stomach
The active Hp infection in stomach was estimated using
13C-Urea Breath Test (UBT) as described previously
[47]. After overnight fast two baseline (prior to urea ad-
ministration) breath samples were collected into testing
vials (Labco exetainer) from each subject. This was follo-
wed by ingestion of gelatine capsule containing 38 mg
of 13C-urea swallowed with 25 ml of water. After 3 min,
each subject drank additional 25 ml of water and breath
samples were again collected after 10 and 20 min upon
the 13C-urea administration. The final results of
13CO2/
12CO2 ratios were measured with the use of isoto-
pe-ratio mass-spectrometry (IRMS, Heliview, Medi-
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chems Seoul, Korea) and were expressed as δ13CO2 (per
mil) values. A change of mean δ13CO2 value over baseli-
ne (DOB) after urea capsule ingestion, of more than 2.5
was considered as positive result.
In all tested subjects, the samples of venous blood were
withdrawn under basal conditions after overnight fast
and the plasma was separated and stored at –70°C until
it was used for further examinations.
Examination of the IgG antibodies against Hp and
CagA protein by enzyme-linked immunosorbent as-
say (ELISA)
The Hp infection status was assessed by determining
IgG antibodies against Hp using commercial rapid enzy-
me linked immunosorbent assay kit (ELISA, BioSource,
Europe S.A.). As recommended by producer, titers hi-
gher than 15 AU/ml were considered positive. The IgG
antibodies to CagA cytotoxins were detected by ‘in ho-
use’ ELISA test using recombinant CagA (gift from Ora
Vax Cambridge, USA) as antigen. The optimal antigen
concentration was 0.5 µg/well and such aliquots were lo-
aded into wells in 96-well microtiterplate. The optimal
dilution of human serum was 1:100 and horseradish pe-
roxidase-conjugated anti-human IgG was used at a dilu-
tion of 1:4000. Titers higher than 0.3 OD were conside-
red as CagA positive.
Determination of plasma IL-8 concentration
Plasma IL-8 levels were measured by ELISA using com-
mercially available kit (BioSource, Europe S.A.) and as-
say was performed according to the manufacture’s in-
structions.
Determination of plasma fibrinogen, cholesterol
and LDL-cholesterol
Plasma obtained from Hp-positive and Hp-negative pa-
tients and control subjects was also examined for con-
centrations of total plasma cholesterol, LDL cholosterol
and fibrinogen (Clauss assay) using standard enzymatic
laboratory methods.
PCR detection of Hp DNA in atherosclerotic plaque
Sample of carotid plaques obtained at carotid artery en-
dartherectomy were stored at –70°C before processing.
DNA extraction was performed using the Trizol Re-
agent according to the manufactures instructions (Gibco
BRL/Life Technology, Eggenstein, Germany). The poli-
merase chain reaction (PCR) was used to identify bacte-
rial DNA with a pair of primers that amplify a specific
DNA region codifying for the 16 S ribosomal RNA of
Hp (sense: 5’-TCA GCC TAT GTC CTA TCA GC-3’;
anti sense: 5’-CAG TAA TGT TCC AGC AGG TC-3’).
The amplified 499 bp product was analysed by gel elec-
troforesis on 1.5% agarose gel stained with ethidium
bromide. As a positive control for Hp the DNA extracted
from pure Hp culture was also amplified. As a negative
control for Hp, the autopsy material from carotid arte-
ries without atherosclerotic changes were used. The re-
action was considered positive when migrating in the
band of molecular weight of the positive controls. Sequ-
ence analysis of the PCR-products confirmed, that the
amplified gene products were specific for Hp.
All Hp CagA(+)/CagA(–) stroke pts and controls rece-
ived standard one week anti-Hp triple therapy (Clarith-
romycin 500 mg bd, Amoxycillin 1000 mg bd and Ome-
prazole 20 mg bd). Six months after successful therapy
confirmed by 13C UBT, serum IL-8 and plasma total
cholesterol, LDL-cholesterol and fibrinogen levels were
again determined in 10 Hp CagA(+)/CagA(–) stroke pts
and 10 control subjects. 
Statistical analysis
Statistical analyses were made by using Mann-Whitney
test to calculate frequency of CagA(+) or CagA(–) Hp in-
fection in studied groups. Kruskal-Wallis and Tuc-
key’s repeated-measures tests, Student’s t-test and Odds
Ratio (OR) were used to compare plasma biochemical
parameters and risk of stroke in Hp infected subjects.
RESULTS
The prevalence of Hp infection, detected by UBT and
confirmed by anty-Hp IgG in studied stroke pts and he-
althy controls, shows that the Hp infection rate was si-
gnificantly higher in stroke pts than in healthy controls
(83.75% vs 65% for UBT and 86.25% vs 67.5% for IgG –
Table 1). The prevalence of CagA positive Hp infection
was also significantly higher in stroke pts than in con-
Hp 13C-UBT
Anti-Hp IgG
Anti-CagA IgG
83.75%*
86.25%*
57.50%*
65.00%
67.50%
33.75%
*p<0.05 indicates the statistical difference between studied groups
Test Stroke ptsControl
Table 1. The prevalence of Hp infection in controls and stroke
pts groups.
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Figure 1. Mean total plasma cholesterol concentrations in Hp
CagA(+), Hp CagA(–), Hp (–) stroke pts and controls
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trols (57.5% vs 33.75%, Table 1). The OR calculated for
Hp infected stroke pts was 2.35 (95% CI; 1.08–6.98).
Figure 1 shows the mean total plasma cholesterol con-
centrations in stroke pts infected with Hp CagA(+) or
CagA(–) and uninfected stroke pts in comparison to
control subjects infected with Hp CagA(+) or Hp Ca-
gA(–) and without Hp infection. In Hp infected CagA(+)
and CagA(–) stroke pts, total plasma cholesterol concen-
trations were significantly higher than in Hp negative
stroke patients (5.69 and 5.43 vs 4.36 mmol/L, respecti-
vely, p=0.007). In stroke pts infected with CagA(+)Hp
strain, mean total cholesterol concentration tended to
reach higher value than that in Hp CagA(–) pts, but the
difference did not reach statistical significance.
Healthy controls infected with Hp CagA(+) or CagA(–)
strains had higher mean total plasma cholesterol con-
centrations 5.52 and 4.99 mmol/L, respectively, than
uninfected subjects (4.19 mmol/L). The highest value of
total plasma cholesterol concentration was observed in
Hp CagA(+) and this was significantly higher than that
recorded in controls infected with Hp CagA(+), the va-
lue in latter group being significantly higher than in Hp
negative controls. The differences in mean total plasma
concentrations reached statistical significance between
each studied subgroup (p<0.001).
Influence of Hp infection on mean plasma concentra-
tion of LDL-cholesterol, another well-known atheroge-
nic factor, in stroke pts and controls is shown on Figure
2. Stroke pts infected with Hp CagA(+) or CagA(–) sho-
wed significantly higher plasma LDL concentration than
Hp-negative stroke pts (p=0.02). The highest value of
LDL-cholesterol concentration i.e. 3.72 mmol/L was ob-
served in stroke patients infected with Hp CagA(+).
Controls infected with Hp CagA(+) or Hp CagA(–) had
also higher LDL-cholesterol concentration in compari-
son to that in uninfected subjects (3.14; 2.93 and 2.70
mmol/L), respectively). There was no statistically signifi-
cant difference in LDL-cholesterol concentrations be-
tween Hp CagA(+) and CagA(–) stroke subjects or con-
trol subgroups, but it was observed between Hp Ca-
gA(+) and Hp negative individuals (p<0.001).
Figure 3 shows the plasma fibrinogen concentrations in
Hp CagA(+) or CagA(–) infected and Hp uninfected
stroke pts and control subgroups. In stroke pts infected
with Hp CagA(+) or CagA(–) and Hp negative mean pla-
sma fibrinogen concentrations were similar and no si-
gnificant difference between these subgroups was obse-
rved. Such differences were observed however between
controls infected with Hp CagA(+) and Hp CagA(–) or
those not infected with Hp (p<0.001). The highest value
of plasma fibrinogen concentration in controls was fo-
und in Hp CagA(+) subgroup (2.89 mmol/L). Plasma fi-
brinogen concentrations detected in all stroke pts sub-
groups (Hp CagA(+), Hp CagA(–) or Hp-negative) were
higher than those obtained in respective control subgro-
ups.
Plasma IL-8 levels in stroke pts infected with Hp Ca-
gA(+) or CagA(–) and in uninfected were significantly
higher than those in respective control subgroups (Figu-
re 4). The mean highest value of plasma IL-8 concentra-
tion was 7.84 pg/ml and it was reached in stroke pts in-
fected with Hp CagA(+) subgroup but this value was not
significantly different from that in CagA(–) or Hp nega-
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Figure 2. Mean total plasma LDL-cholesterol concentrations in Hp
CagA(+), Hp CagA(–), Hp (–) stroke pts and controls
Figure 3. Mean total plasma fibrinogen concentrations in Hp CagA(+),
Hp CagA(–), Hp (–) stroke pts and controls
Figure 4. Mean total plasma IL-8 levels in controls and stroke pts
respectively in subgroups Hp CagA(+), Hp CagA(–), Hp (–).
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tive stroke pts (Figure 5). No statistically significant dif-
ference in IL-8 was also found between subgroups of Hp
positive CagA(+) or CagA(–) and Hp negative healthy
controls (Figure 5).
Figure 6 shows the ethidium bromide-stained 1.5% aga-
rose gel electrophoresis. DNA product for Hp,
16S rRNA, was not detected in five Hp negative controls
taken at autopsy from subjects without carotid atherosc-
lerotic plaques. DNA for Hp 16S rRNA was found in
atherosclerotic plaques of 5 out of 20 (25%) tested stro-
ke patients with carotid endarterectomy.
Table 2 shows the plasma concentrations of total chole-
sterol, LDL-cholesterol, fibrinogen and serum IL-8 le-
vels in 10 Hp CagA(–) and 10 Hp CagA(+) control sub-
jects before and 6 months after successful (based on ne-
gative UBT) standard anti-Hp therapy. In Hp CagA(–)
subgroup there was no statistical difference in plasma
concentrations of total cholesterol, LDL-cholesterol and
fibrinogen before and after therapy, but mean plasma
IL-8 level was statistically diminished in those subjects
after therapy. In control Hp CagA(+) subjects total pla-
sma cholesterol and IL-8 levels were statistically redu-
ced 6 months after anti-Hp therapy, but reduction in
plasma LDL-cholesterol and fibrinogen concentrations
tended to decrease but this failed to reach statistical si-
gnificance.
Table 3 shows the plasma concentrations of total chole-
sterol, LDL-cholesterol and fibrinogen and plasma IL-8
level in 10 Hp Cag(–) and 10 Hp Cag(+) stroke patients
before and 6 months after successful standard anti-Hp
triple therapy. In both subgroups plasma concentra-
tions of total cholesterol, LDL-cholesterol and serum
IL-8 were significantly decreased 6 months after anti-Hp
therapy. Only plasma fibrinogen concentrations was not
significantly affected 6 months after anti-Hp therapy in
these stroke patients.
DISCUSSION
Our study provides an evidence for the possible implica-
tion of Hp infection in cerebrovascular stroke via enhan-
cing some risk factors of atherogenesis.
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Figure 5. Mean serum IL-8 levels in Hp CagA(+), Hp CagA(–), Hp (–)
stroke pts and controls
Figure 6. Analysis of the PCR products for Hp 16S rRNA. Molecular marker (line M), five Hp negative subjects (lines 1–5), five Hp positive patients
(lines 6–10) and Hp DNA positive control (line 11). Electrophoresis in ethidium bromide stained 1, 5% agarose gel. Molecular weight of
product generated with primers (sequence given in Methods section) is 499 bp.
Hp Cag A(–)
Hp Cag A(+)
NS
NS
NS
0.017
0.003
NS
NS
0.03
Total cholesterol
LDL cholesterol
Fibrinogen
IL-8
Total cholesterol
LDL cholesterol
Fibrinogen
IL-8
4.80±0.66
2.99±0.61
2.73±0.19
6.11±2.48
5.46±1.14
3.16±0.78
2.65±0.72
5.77±1.36
4.89±0.83
2.83±0.67
2.50±0.53
4.25±1.58
4.99±1.07
3.04±0.61
2.50±0.53
5.00±1.07
Parameter Before treatment X±SD After treatment p
Table 2. Mean (±SD) of plasma and serum levels of total cholesterol, LDL-cholesterol, fibrinogen [mmol/l] and IL-8 [pg/ml] in the same
10 Hp Cag A(–) and 10 Hp Cag A(+) control subjects before and 6 months after the Hp eradication.
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Several previous studies were carried out to investigate
the relationship between Hp seropositivity associated
with Hp infection and both, coronary heart and cerebro-
vascular diseases risk factors. The results obtained favo-
red an association of chronic gastric Hp infection, espe-
cially expressing CagA cytotoxins, with ischemic heart
disease and ischemic stroke [9,16,34,48]. In our present
study we confirmed a higher prevalence of Hp infection
in patients with ischemic cerebral disease as compared
to age- and gender-matched controls. Moreover, we fo-
und a significantly higher prevalence of more virulent
Hp CagA positive strains in ischemic stroke pts as com-
pared to healthy controls.
Recently, new approach has been attempted to explain
the pathomechanism of the heart and cerebral vessel
atherosclerosis in relation to extradigestive manifesta-
tion of chronic infection with Hp. Various mechanisms
by which Hp could increase the risk of arterial plaque
formation have been proposed. At present, the data
support both indirect and direct effects of bacterial in-
fection on atherogenesis [29,49]. Hp infection could re-
sult in a low grade chronic inflammatory process in va-
scular endothelium and this could promote atherogenic
changes by altering some major vascular risk factors
such as fibrinogen and plasma lipid fractions [16,50,51].
In our study, the Hp seropositivity correlated with in-
creased total plasma cholesterol concentration not only
in stroke pts but also in control subjects. Similar associa-
tion was also observed with respect to plasma LDL-cho-
lesterol concentrations which were significantly elevated
in Hp infected stroke pts and control groups, especially
in Hp subjects infected with more virulent CagA positive
strains, being in agreement with the data published else-
where [9,31,52]. Our finding supports the hypothesis
that chronic Hp infection may modify the plasma lipid
profile in a way that increases the risk of atherosclerosis.
Underlying processes that might explain the association
between infectious agents and atherosclerosis remain
still unclear and they are the subject of debate. Feingold
et al [35] postulated that chronic infection may alter li-
pid profile in an atherogenic direction via the action of
proinflammatory cytokines such as IL-1 and IL-6, inter-
feron α and TNFα that are capable to affect lipid meta-
bolism in different ways. They suggested that cytokines
may activate adipose tissue lipoprotein lipase, stimulate
hepatic fatty acid synthesis and influence lipolysis. Basso
and his colleagues [53] observed significantly higher po-
lymorphonuclear leukocyte oxidative burst in Hp infec-
ted patients than in Hp negative or healthy controls.
This indicates that free radical formation could also play
an important role in atherogenesis. It has also been
shown that Hp infected subjects exhibit the decreased
level of antioxidants [54]. These events may be associa-
ted with elevated lipid peroxydation, especially LDL
fraction, which could be an important mechanism lin-
king Hp infection and various phases of atherosclerotic
plaque formation via elevated oxidized LDL levels [55].
In the present study the plasma fibrinogen concentra-
tion was not influenced by Hp infection in stroke pts or
healthy controls, but the plasma fibrinogen was signifi-
cantly higher in Hp positive stroke patients than in Hp
negative controls. Our study is in keeping with results
obtained by other authors [16,56–58] that the higher va-
lue of plasma fibrinogen concentration was observed in
Hp infected CagA positive subjects than in uninfected
controls. Hp may be a life-long bacterial infection of the
gastric mucosa, that is mainly acquired in childhood [3].
Fibrinogen is an acute phase protein and its level stron-
gly corresponds to the process of atherogenesis. Fibri-
nogen seems to participate directly in early phases of
atherosclerotic plaque formation and arterial thrombo-
sis [59,60]. Moreover, fibrinogen is one of the more im-
portant components of the acute and chronic inflamma-
tory responses [61]. Our finding suggests that fibrino-
gen level may slowly and gradually increase during pro-
longed chronic Hp infection and may be related to the
length of disease. Zito et al [56] and Patel et al [57] sho-
wed increased levels of plasma fibrinogen in Hp infected
individuals even after controlling for possible confoun-
ding factors related to either infection or fibrinogen.
Bierti and colleagues [62] also found a significantly hi-
gher mean plasma fibrinogen level in Hp infected than
uninfected individuals. Moreover, they found higher le-
vels of factor VII and protrombin cleavage fragment in
Hp positive subjects. There are, however, conflicting re-
sults whether treatment of Hp gastric mucosa infection
decreases plasma fibrinogen concentrations. Treiber
[63] and Torgano et al [64] observed beneficial effect of
Hp eradication in patients with ischemic heart disease.
Oderda et al [65] failed to detect the increased plasma
fibrinogen concentration in Hp infected children when
compared to Hp negative controls, but significant decre-
ase in plasma fibrinogen levels were observed after Hp
Hp Cag A(–)
Hp Cag A(+)
0.007
0.04
NS
0.04
0.008
0.06
NS
0.016
Total cholesterol
LDL cholesterol
Fibrinogen
IL-8
Total cholesterol
LDL cholesterol
Fibrinogen
IL-8
6.22±1.12
3.67±0.81
3.01±0.88
7.84±1.60
6.61±0.73
3.65±0.82
3.43±0.44
8.75±4.29
4.71±0.36
2.75±0.45
3.29±0.49
5.75±1.58
5.23±1.07
2.86±0.78
3.00±0.82
6.38±3.34
Parameter Before treatmentX±SD
After treatment
X±SD p
Table 3. Mean (±SD) of plasma and serum levels of total cholesterol, LDL-cholesterol, fibrinogen [mmol/l] and IL-8 [pg/ml] in the same 
10 Hp Cag A(–) and 10 Hp Cag A(+) patients before and 6 months after the successful Hp eradication.
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eradication and no change, but a mild increase when in-
fection persisted. Higher plasma fibrinogen concentra-
tions were, however, seen in older Hp positive children
suggesting that this observation may be related to the
length of disease. The importance of this finding is hi-
ghlighted by the possibility of an effective pharmacolo-
gical intervention against Hp to decrease the levels not
only plasma fibrinogen concentration but also some oth-
ers acute and chronic mediators of inflammation as well
as atherogenesis [65]. Other authors failed to observe
the significant association between Hp infection and the
elevated plasma fibrinogen level [66–68]. However, in
some of Hp positive subjects a spontaneous rise in fibri-
nogen plasma concentration was observed and this co-
uld influence the stability of ischemic heart disease [63].
In other studies the association between chronic Hp in-
fection and hemostatic system has been examined. In-
creased levels of circulating activated platelets and pla-
telet aggregates were found in pts who were Hp seropo-
sitive and also platelet P-selectin expression was enhan-
ced in Hp infected human and mice [69]. Moreover,
chronic infection of mice with Hp lead to increased
thrombi formation resulting in embolism after damage
to arterioles [70]. Therefore, platelet activation and ag-
gregation observed in humans and experimental ani-
mals may contribute to the microvascular dysfunction
associated with Hp infection. This phenomenon as well
as plasma fibrinogen alterations could be, at least in
part, explanatory to the pathogenesis of Hp infection in
atherogenesis.
Over the past few years, a growing body of evidence has
stressed the role of inflammation in the pathophysiology
of atherosclerosis and acute ischemic stroke [71–75].
Most inflammatory reactions have been attributed to cy-
tokines, such as interleukins, that are responsible for up
regulation of adhesion molecules, recruitment and acti-
vation of leucocytes, promotion of leukocyte-endothe-
lium interaction and conversion of local endothelium to
a prothrombotic state [72]. These mediators are also
able to change the hemostatic system by increasing the
expression of procoagulant substances (fibrinogen, pla-
sminogen activator inhibitor-1) [76], down regulating
the fibrinolitic system [77] as well as they could cause
a prolonged endothelial dysfunction [78]. Cytokines
may also affect lipid metabolism by liver stimulation of
fatty acid synthesis and lipolysis in adipocytes resulting
in proatherogenic alteration in plasma lipid profile [35,
37,38].
Increased synthesis of IL-8 was observed in acute ische-
mic stroke up to one month after onset of symptoms,
however this, has not been restricted to the ischemia of
central nervous system (CSN), but also could be detec-
ted systemically [46,79–81]. IL-8 is a well-known chemo-
kine that promotes invasion of leucocytes into the brain.
The activation by IL-8 or proteases and free radicals
formation due to infiltration of neutrophils into the ce-
rebral tissue might augment the production of oxygen
or nitrogen reactive species as well as lipid peroxydation
and subsequently neuronal damage [80]. This remains
in agreement with the observation of increased IL-8
concentration in cerebrospinal fluid (CSF) compared
with plasma in pts with ischemic stroke indicating that
IL-8 in this pts is predominantly of CNS origin, proba-
bly at the site of the neuronal tissue damage. Further-
more, following the CSN injury, the blood-brain barrier
may become leaky, and this could facilitate the entry of
activated circulating immune cells into the CSN to gene-
rate reactive oxygen species [82].
A strong systemic response as reflected by increased se-
rum levels of IL-8, IL-1β, IL-6, TNF-α in stroke pts
may indicate a possible role for systemic cells regarding
the production of cytokines within CSN [73,83]. An in-
flammatory process in peripheral tissues distal from the
CSN that occurs parallelly to the ischemic event e.g.
concomitant infection may result in increased levels of
cytokines derived by activated peripheral blood mono-
nuclear cells (PMBC). Numbers of activated PMBC in
the CSN strongly correlate with the severity of the ische-
mic event [46]. Systemic up-regulation of cytokine
expression may contribute to the pathogenesis of ische-
mic stroke through a potentiation of the secondary in-
flammatory process [46].
In Hp infected individuals increased levels of IL-8 are
regularly detected. The major source of IL-8 in Hp in-
fected gastric mucosa are neutrophils and epithelial
cells. IL-8 and many others released cytokines, especial-
ly TNFα, probably contribute to the enhanced gastrin
release and gastric acid secretion [84-86]. Most of im-
munological responses are strongly enhanced by Hp
strain expressing cagA and vacA encoded cytokines
[9,87,88].
Our study failed to show any statistical significant diffe-
rences in mean plasma IL-8 concentration between Hp
CagA(+) and Hp CagA(–) stroke pts or controls and in
Hp negative pts and controls. However, in all these sub-
groups the overall levels of IL-8 were significantly hi-
gher in stroke pts as compared to healthy subjects.
Thus, after ischemic stroke plasma IL-8 concentrations
rise about twofold in each studied Hp infected or unin-
fected subgroup. The highest values of IL-8 concentra-
tion were reached in Hp CagA(+) subgroup. These re-
sults indicate that acute local neural tissue necrosis and
inflammation is accompanied by enhanced systemic
expression of IL-8 that in turn may play an important
role in ischemic brain injury. The higher concentration
of IL-8 in Hp positive pts, predominantly in those infec-
ted with Hp strains expressing CagA are more prone to
develop ischemic stroke and preexisting Hp infection
may correlate with severity and long term clinical outco-
me of stroke.
It has been also proposed that cytokines such as IL-8
and TNFα and acute phase inflammatory response re-
actants are significantly higher in Hp infected coronary
artery disease (CAD) pts than in control subjects [89].
This correlation is enhanced in Hp CagA(+) infected
CAD pts. Pasceri et al [9] and Kowalski et al [89] have
proposed that long term persistent infection with cyto-
toxic Hp strain enhances atherosclerotic process thro-
ugh synthesis of acute phase reactants.
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In the present study the Hp positive control subjects
and stroke patients received standard anti-Hp therapy
and after 6 months we again determined plasma con-
centrations of total cholesterol, LDL-cholesterol, fibrino-
gen and serum level of IL-8. In control subjects we fa-
iled to observe any alterations in plasma concentrations
of atherogenic risk factors, but in stroke patients lipid
plasma parameters were significantly reduced. After
therapy there was also significant reduction in serum
IL-8 level in both Hp Cag(–) and Cag(+) control and
stroke pts subgroups, respectively. These results indica-
te the possible beneficial influence of anti-Hp therapy on
the plasma levels of atherogenic and inflammatory stro-
ke risk factors. The traditional risk factors explain the
origin of about half of atherosclerotic plaques [90] and
new approaches to the discovery of additional unexpla-
ined causes of atheromatic and thrombotic events sho-
uld be elucidated. Bacteria such as Chlamydia pneumoniae
and Hp and also hereditary predisposition to these in-
fections are considered as independent factors of caro-
tid plaque formation [91-92]. The question remains
whether chronic or repeated treatment of bacterial in-
fections could successfully eradicate chronic infection or
prevent bacterial reinfections and in consequence redu-
ce their influence on systemic atherosclerotic plasma
risk factors and acute and chronic inflammatory reac-
tions, which are key events in atherosclerotic plaque for-
mations. This seems to be unlikely that treatment of
such infections would be the sole or main way to pre-
vent atherosclerosis but could be considered in the futu-
re as one of the important factors in ischemic stroke and
in primary or secondary prevention of this disease.
In our study we investigated the presence of Hp in 20
atherosclerotic plaques obtained at carotid endarthe-
rectomy using highly sensitive polimerase chain reac-
tion method. The DNA for Hp 16S rRNA was found in
5 of 20 (25%) atherosclerotic plaques. This finding indi-
cates that bacterial infection occurring within the vessel
wall may be directly implicated in the pathophysiologi-
cal cascade leading to atherosclerosis through the pro-
cesses such as initiation, progression and/or destabiliza-
tion of atherosclerotic plaque and also via the initiation
of athero-thrombotic events around the destroyed arte-
rial wall.
Recently, further studies involve the direct implication
of Hp infection in atherogenesis. Hp produces 60 kDa
heat shock proteins which have a high degree of sequ-
ence homology with human 60 kDa heat shock proteins
expressed in atherosclerotic lesions [93-94]. Cross reac-
ting antibodies to heat shock proteins are a risk factor
for carotid atherosclerosis and may be relevant for the
pathogenesis of the vessel damage [95]. The existence of
putative antigenic mimicry between atherosclerotic pla-
ques and Hp antigens existed in serum of infected indi-
viduals was also shown by Cammarota [96]. Hp anti-Ca-
gA antibodies cross-reacting specifically with two high
molecular weight vascular antigens were discovered by
Franceschi [97]. Binding of anti-CagA antibodies to tho-
se antigens in injured arteries could influence the pro-
gression of atherosclerosis in CagA positive Hp infected
pts. There are now also growing evidences for the pre-
sence of specific Hp DNA in atherosclerotic plaques de-
tected by PCR [98-100].
In summary we found that chronic, especially Hp Ca-
gA(+) infection, seems to be more prevalent in stroke
pts than in healthy population. Chronic Hp infection
may raise total plasma cholesterol and LDL-cholesterol
levels which are considered as a risk factors of atherosc-
lerosis. Chronic Hp infection enhances plasma fibrino-
gen concentration and, therefore, may increase blood
viscosity and promote clot formation in Hp positive per-
sons. Deleterious effect of chronic Hp infection and stro-
ke may be attributed to the higher generation of IL-8,
because this cytokine levels are positively correlated
with the severity of stroke and in consequence with cli-
nical outcome. Hp infection with CagA(+) strain exhibit
the highest modulating influence on studied levels of
plasma risk factors of atherogenesis. Anti-Hp therapy
may have beneficial influence on atherogenic and in-
flammatory plasma biochemical stroke risk factors. Hp
infection occurring within the arterial wall may be direc-
tly implicated in the atherosclerotic processes.
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